For richer charts and full features, open SpikePanel on desktop.
Graded daily on value D-, growth C+, profitability C-, momentum B, revisions A-. Sector-relative, identical for every user.
Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $NKTR are available with SpikePanel Pro.
Key events, in time order
Three PhIII in atopic dermatitis started; pivotal alopecia study due December
Q3 loss beats estimates, but lower FY26 revenue view pressures shares
EADV data show sustained hair regrowth after stopping, supporting Phase III trial
Federal jury finds Lilly breached implied covenant; award subject to post-trial and appeal
FDA grants single AA Phase 3 path, AtD program doubles as safety database, reducing trials
LLY lawyers push for BD/partnership docs post-Feb 2026; pretrial battle intensifies
Q2 loss beat but revenue missed; cash strong; Phase 3 ZENITH-AD underway, data mid-2028
rezpeg治疗中重度特应性皮炎的全球III期ZENITH AD项目已于7月启动,前两项研究开始随机入组,第三项研究预计9月底启动;顶线数据预计2028年中读出,若阳性则2029年提交BLA。
Quarterly results provide updates on financials and pipeline progress.
None yet
None yet
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice